PHARMASSET - Another Step Towards Success!
Pharmasset (VRUS) announced top line data of PSI-7977 PhIIb, PROTON study (PSI-7977 400mg, QD + Peg-IFN/RBV) in HCV genotype-1 treatment naïve pts and Initiation of IFN-free PhIIb trial of PSI-7977 and PSI-938. Result promises of many advantage over launched PI’s (Incivek/vertex/JNJ and Victrelis/Merck) and others in the pipeline. For more details, please read our report released on 13th September, 2011 on VRUS titled “Another Step Towards Success”.
COMPANIES MENTIONED
PHARMASSET
PHARMASSET
More Publications
AZN/BMY acquisition of Amylin – A step towards leadership in diabetes space
US$ 90.00
June 2012
2 pages
